European and Mexican patents for Generex Biotech
USA-based Generex Biotechnology, a leader in drug delivery for metabolic diseases through the inner lining of the mouth, has been awarded new patents in Europe and Mexico.
The European Patent Office granted the company its fourth European patent titled, Proteinic Drug Delivery System Using Membrane Mimetics. The patent has been validated in nine European countries including the UK, France and Italy, and contains formulation and process claims for a mixed-liposome pharmaceutical compound.
Additionally, the Mexican Institute of Intellectual Property granted the company its ninth Mexican patent tilted, Mixed Micellar Delivery System and Method of Preparation. This contains formulation and process claims for a pharmaceutical composition suitable for delivery through mucosal membranes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze